Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac...
18 insider purchases on record · latest filing 2025-12-30.
Insiders have also filed 3 sale transactions at FBRX.